Roth Positive on Retrophin's (RTRX) Thiola Licensing Deal; Issues Commentary
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Retrophin (RTRX) Enters Agreement for Thiola Marketing Rights in U.S.; Boosts Outlook
May 29, 2014 4:43 PM EDTRetrophin, Inc. (NASDAQ: RTRX) announced that it has entered into a license agreement with Mission Pharmacal Company, a private company based in San Antonio, Texas, for U.S. marketing rights to Thiola (tiopronin). Financial terms of the agreement were not immediately disclosed.
Thiola® is approved by the U.S. Food and Drug Administration for the treatment of cystinuria, a rare genetic cystine... More
